Securities code: 600867 securities abbreviation: Tonghua Dongbao Pharmaceutical Co.Ltd(600867) No.: 2022-008 Tonghua Dongbao Pharmaceutical Co.Ltd(600867)
Announcement on the implementation results of share repurchase and share change
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear individual and joint liabilities for the authenticity, accuracy and completeness of its contents. 1、 Review and approval of repurchase and contents of repurchase plan
Tonghua Dongbao Pharmaceutical Co.Ltd(600867) (hereinafter referred to as “the company” and ” Tonghua Dongbao Pharmaceutical Co.Ltd(600867) “) held the 16th meeting of the 10th board of directors on July 29, 2021, deliberated and adopted the proposal on the scheme of repurchasing the company’s shares by means of centralized bidding transaction. The proposal has been deliberated and approved at the first extraordinary general meeting of shareholders in 2021 held on August 25, 2021. On August 26, 2021, the company disclosed the report of Tonghua Dongbao Pharmaceutical Co.Ltd(600867) on repurchasing the company’s shares by means of centralized bidding transaction. For the above contents, see the company’s website at Shanghai Stock Exchange (http: / / www.sse. Com. CN.) And relevant announcements disclosed by designated media (announcement numbers: 2021-045, 2021-046, 2021-055 and 2021-057 respectively).
The main contents of this share repurchase plan: the company uses its own funds to repurchase RMB common shares (A shares) in the form of centralized bidding transaction. The number of repurchased shares shall not be less than 12 million shares (inclusive) and not more than 24 million shares (inclusive), accounting for 0.59% and 1.18% of the total share capital of the company. Repurchase the company’s shares at a price of no more than 15 yuan / share (inclusive), and the maximum repurchase capital is 360 million yuan (inclusive). The repurchase period is within 6 months from the date when the shareholders’ meeting deliberates and approves the share repurchase plan. The shares after the repurchase will be cancelled and the registered capital of the company will be reduced.
2、 Implementation of repurchase
(I) on September 2, 2021, the company implemented the share repurchase for the first time, and disclosed the announcement of Tonghua Dongbao Pharmaceutical Co.Ltd(600867) on the first repurchase of the company’s shares by means of centralized bidding transaction (Announcement No.: 2021-062) on September 3, 2021.
(II) on January 28, 2022, the company completed the repurchase. The total number of shares repurchased by the company is 2399946, accounting for 1.18% of the total share capital of the company. The highest price of transaction is 12.43 yuan / share, the lowest price of transaction is 10.12 yuan / share, and the total amount paid is 263887209.31 yuan (excluding transaction expenses).
(III) there is no difference between the actual implementation of this repurchase plan and the originally disclosed share repurchase plan
The company has completed the repurchase according to the disclosed plan.
The number of shares actually repurchased, the repurchase price and the total amount of funds used are in line with the deliberation and approval of the general meeting of shareholders
Repurchase program. This repurchase will not have a significant impact on the company’s operation, finance and future development
It will affect the listing status of the company and will not lead to changes in the control of the company.
3、 Shares bought and sold by relevant entities during the repurchase period
On July 30, 2021, the company disclosed the repurchase of shares for the first time. See Tonghua Dongbao Pharmaceutical Co.Ltd(600867) the 10th board of directors for details
Announcement on the resolution of the 16th meeting of the board of directors (Announcement No.: 2021-045) and Tonghua Dongbao Pharmaceutical Co.Ltd(600867) about Yiji
Announcement on the share repurchase scheme of the company through competitive trading (Announcement No.: 2021-046). As of the company
Prior to the disclosure of the report, the directors, supervisors, senior executives, controlling shareholders, actual controllers and share repurchase proponents did not buy shares during this period
Selling company shares.
4、 This share cancellation arrangement
Upon the application of the company, the company will be registered in Shanghai of China Securities Depository and Clearing Co., Ltd. on February 8, 2022
The branch company cancelled 2399946 shares repurchased this time and went through the formalities of change registration in time
Appropriate.
5、 Statement of changes in shares
The total number of shares repurchased this time is 2399946. According to the share repurchase plan, the repurchase will be cancelled
The changes of the company’s shares before and after share purchase and cancellation are as follows:
Total number of shares cancelled before this repurchase
Number of shares of stock type in total share capital proportion of shares cancelled this time in total share capital (%) (share) (share) (%)
Shares with limited sales conditions 6990000.34 0 6990000.35
Shares with unlimited sales conditions 2026998517 99.66 – 2399946 2002998571 99.65
Including: special securities account for repurchase 33999925 1.67 – 2399946 9999979 0.50
Total share capital 2033988517 100.00 – 2399946 2009988571 100.00
Note: before this repurchase, the company also implemented the repurchase on February 5, 2021 and March 31, 2021
The repurchase was completed, and 9999979 shares were repurchased through centralized bidding transaction, which was completed on April 2, 2021
The announcement on the implementation results of Tonghua Dongbao Pharmaceutical Co.Ltd(600867) share repurchase (Announcement No.: 2021-021) was disclosed on the th. The repurchased shares will be used for equity incentive and / or employee stock ownership plan. The above shares are currently deposited in the company’s special account for repurchase.
6、 Documents for future reference
The inquiry certificate of the number of shares held in the special securities account for repurchase issued by China Securities Depository and Clearing Co., Ltd.
It is hereby announced.
Tonghua Dongbao Pharmaceutical Co.Ltd(600867) board of directors February 8, 2002
